Congenital hyperinsulinism refers to a genetic disorder in which the pancreas produces abnormally high levels of insulin, leading to low blood sugar or hypoglycemia. The incidence of this condition is estimated to be around 1 in 25,000 to 1 in 50,000 live births in the general population. In certain populations with high rates of consanguinity, the incidence of congenital hyperinsulinism can go as high as 1 in 2,500. Existing medications often fail to reach optimal glycemic control or show significant side effects. Thus, there is a need for new drugs that can safely and effectively manage the activity of insulin and address other complications associated with congenital hyperinsulinism.
The Congenital Hyperinsulinism (CHI) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into congenital hyperinsulinism (CHI) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for congenital hyperinsulinism (CHI). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The congenital hyperinsulinism (CHI) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from congenital hyperinsulinism (CHI).
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to congenital hyperinsulinism (CHI).
Congenital hyperinsulinism is the most common cause of persistent elevated levels of insulin or hypoglycemia in neonates, infants, and children. In this condition, the beta cells in the pancreas secrete too much insulin. Frequent episodes of hypoglycemia can cause lethargy, shakiness, difficulty feeding, and seizures.
Treatment for congenital hyperinsulinism includes medications such as chlorothiazide, glucagon, diazoxide, and octreotide. Studies reveal that this treatment is effective in around half of the children. However, if the patient fails to respond to medical therapy, surgical intervention is an option. Moreover, since congenital hyperinsulinism demonstrates heterogeneity in disease presentation and treatment response, there is a growing focus on the development of personalized medicine approaches that can address these genetic differences.
This section of the report covers the analysis of congenital hyperinsulinism (CHI) drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for congenital hyperinsulinism (CHI).
The drug molecule categories covered under the congenital hyperinsulinism (CHI pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for congenital hyperinsulinism (CHI).
The EMR report for the congenital hyperinsulinism (CHI) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in congenital hyperinsulinism (CHI) clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Zealand Pharma, the primary objective of this open-label, multicenter Phase III clinical trial is to assess the long-term safety of the drug candidate dasiglucagon administered as a subcutaneous infusion in an estimated 44 children with congenital hyperinsulinism.
Rezolute is conducting a Phase III clinical trial aimed at investigating the safety and efficacy of RZ358 for ...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Congenital Hyperinsulinism (CHI) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for congenital hyperinsulinism (CHI). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within congenital hyperinsulinism (CHI) pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share